These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 30568427)

  • 21. The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis.
    Amaro R; Panagiotaraka M; Alcaraz V; Torres A
    Expert Rev Respir Med; 2018 Aug; 12(8):683-691. PubMed ID: 30010445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
    Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
    Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
    Tay GT; Reid DW; Bell SC
    Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
    Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
    Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
    Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
    Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
    [No Abstract]   [Full Text] [Related]  

  • 28. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.
    Cartlidge MK; Hill AT
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1091-1097. PubMed ID: 28778139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled tobramycin for chronic infection with pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.
    Sangiovanni S; Morales EI; Fernández-Trujillo L
    Respir Med; 2021 Jan; 176():106283. PubMed ID: 33307314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis.
    Tejada S; Campogiani L; Solé-Lleonart C; Gómez A; Gallego M; Vendrell M; Soriano JB; Rello J
    Eur J Intern Med; 2021 Aug; 90():77-88. PubMed ID: 33947626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis.
    Chalmers JD; Boersma W; Lonergan M; Jayaram L; Crichton ML; Karalus N; Taylor SL; Martin ML; Burr LD; Wong C; Altenburg J
    Lancet Respir Med; 2019 Oct; 7(10):845-854. PubMed ID: 31405828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis.
    Rubin BK; Williams RW
    Respiration; 2014; 88(3):177-84. PubMed ID: 25171580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
    McShane PJ; Weers JG; Tarara TE; Haynes A; Durbha P; Miller DP; Mundry T; Operschall E; Elborn JS
    Pulm Pharmacol Ther; 2018 Jun; 50():72-79. PubMed ID: 29621625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhaled antibiotics in the treatment of noncystic fibrosis bronchiectasis].
    Martínez García MÁ; Soler Cataluña JJ; Serra PC
    Arch Bronconeumol; 2011 Jun; 47 Suppl 6():19-23. PubMed ID: 21703475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children.
    Snijders D; Calgaro S; Bertozzi I; Quartesan S; Kozuh I; Lunardi F; Barbato A
    Int J Immunopathol Pharmacol; 2013; 26(2):529-34. PubMed ID: 23755770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection].
    Tabernero Huguet E; Gil Alaña P; Alkiza Basañez R; Hernández Gil A; Garros Garay J; Artola Igarza JL
    Rev Esp Geriatr Gerontol; 2015; 50(3):111-5. PubMed ID: 25724860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.